What You Need to Know about the Johnson & Johnson Vaccine Pause
The following message is adapted from today's COVID-19 Community Corps update from the Department of Health and Human Services:
On Tuesday, April 13, 2021, the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) announced they are reviewing data involving a small number of reported cases of a rare and serious type of blood clot in individuals after receiving the Johnson & Johnson (J&J) vaccine. Out of an abundance of caution, FDA and CDC recommended a pause in the use of the J&J vaccine as they review the data.
The news about the J&J vaccine pause does not affect the two other vaccines that are widely used in the United States – Pfizer and Moderna. More than 100 million people in the United States have been vaccinated safely with these vaccines over the past several months.
As of today, April 15, 2021, here's what's important to know about the J&J vaccine pause:
-
These blood clots are extremely rare. At the time of the announcement, a small number of cases (6) were reported out of the nearly seven (7) million doses of the J&J vaccine administered so far in the United States.
-
Those who received the J&J vaccine have a very low risk for developing blood clots. That said, those who received the J&J vaccine in the last three weeks are advised to be on the lookout for possible symptoms of a clot, which the CDC describes, here.
-
There is still confidence in the overall supply of COVID-19 vaccines for the country. The Administration has secured enough Pfizer and Moderna doses for 300 million Americans, and there is more than enough supply to continue the current pace of vaccinations of three million shots per day. For people who already have appointments for J&J vaccines, state and federal partners are working to get these appointments rescheduled for a Pfizer or Moderna vaccine.
-
Here's the bottom line: The COVID-19 vaccines have already saved lives, and we still have vaccine options that are safe and effective. Americans should continue to get vaccinated as soon as possible.
You can view and share these FDA/CDC resources with your community:
Learn More by Registering for HUD COVID-19 Vaccine Webinar Series
Wednesday afternoons in April, PIH and HUD's Office of Field Policy and Management (FPM) are hosting a webinar series to share information about local efforts to increase access to COVID-19 vaccines for public housing residents and other vulnerable groups.
Join us for the next session on April 21 at 2 pm ET by registering below. Please note that registration is required.
|
A Vaccine Near You: Community-Based Access Strategies
April 21, 2021 | 2:00 – 3:30 pm (ET)
This webinar will feature housing/health vaccine partnerships, with speakers from the National Center for Health in Public Housing (NCHPH) and innovative vaccine access and distribution models from PHAs across the country. Models will focus on key considerations for coordinating local access for HUD-assisted populations. We will be addressing the latest developments with the J&J vaccine as they relate to community collaborations.
Work with your Health Center to Vaccinate!
Through the Health Center COVID-19 Vaccine Program, 1,470 community health centers across the country have been invited to receive and distribute additional federally provided vaccines to their communities, many of which serve public housing and other HUD-assisted residents.
You can partner with your local health center to improve vaccine confidence and access in your community through public health and vaccine distribution events.
Want to receive regular PIH COVID-19 Bulletins?
|